Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Published in Clinical Imaging, the responses indicate that Trump administration policies have made it more difficult to acquire funding and collaborate with other researchers.
More than 5,000 women were interviewed about their eating habits from 1985 to 1991, and then researchers followed up with them 30 years later. The full study was published in Alzheimer’s and Dementia.
Even as TAVR continues to build momentum as the go-to treatment option for many patients, researchers are keeping a close eye on the long-term safety and effectiveness of SAVR.
Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.
New research is providing a broader understanding of how cardiovascular disease risk manifests following pregnancy. Having obesity before and during early pregnancy appears to be a strong indicator of risk for developing future cardiovascular disease and was significantly linked with adverse outcomes during pregnancy.
